🤝 Caring Cross will provide technology, materials, and training to Fiocruz to manufacture CAR-T therapies in Brazil.
💰 The aim is to reduce costs by simplifying and streamlining the manufacturing process.
🌍 The partnership will also provide access to critical materials and training for other organizations in Latin America.
🏭 The manufacturing operation will be located in Rio de Janeiro, operated by Fiocruz’s unit, Bio-Manguinhos.
👍 The collaboration will initially focus on making cell therapies for leukemia and lymphoma, with plans to expand to HIV cell therapy.
Introduction:
Patients in Brazil will soon have increased access to CAR-T therapies as Caring Cross, a U.S. non-profit organization, partners with Fundação Oswaldo Cruz (Fiocruz), a government-backed biomedical research institution, to establish manufacturing capacity in Brazil. The collaboration aims to develop production capacity for CAR-T cell and stem cell gene therapies in the country.
- Caring Cross will provide Fiocruz with the technology, materials, and training needed to manufacture CAR-T cell therapies, including their proprietary lentiviral vectors.
- The partnership aims to reduce the cost of CAR-T manufacturing by implementing a more simplified and robust cell process.
- The manufacturing operation will be based in Rio de Janeiro, Brazil, at a facility operated by Fiocruz’s immunobiologics unit, Bio-Manguinhos.
- Initially, the focus will be on making cell therapies for leukemia and lymphoma, with plans to produce an HIV cell therapy in the future.
- The collaboration will not only increase capacity in Brazil but also provide critical materials and training for CAR-T cell manufacturing across Latin America.
Conclusion:
The partnership between Caring Cross and Fiocruz will establish manufacturing capacity for CAR-T cell therapies in Brazil, aiming to increase access to these treatments for patients. By implementing a simplified and cost-effective manufacturing process, the collaboration hopes to reduce the cost of CAR-T therapies. This initiative is not only important for Brazil but also for the entire Latin America region, as it will provide critical materials and training to other organizations interested in manufacturing CAR-T cells. Overall, this collaboration has the potential to significantly impact the availability and affordability of CAR-T therapies in the region.
